Nordea Investment Management AB Acquires 5,385 Shares of Haemonetics Co. (NYSE:HAE)

Nordea Investment Management AB boosted its holdings in Haemonetics Co. (NYSE:HAE) by 5.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 104,175 shares of the medical instruments supplier’s stock after buying an additional 5,385 shares during the quarter. Nordea Investment Management AB’s holdings in Haemonetics were worth $8,152,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its position in Haemonetics by 6,573.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock worth $70,267,000 after purchasing an additional 836,623 shares in the last quarter. FMR LLC grew its position in Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares during the last quarter. Wellington Management Group LLP raised its position in Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Haemonetics by 75.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock valued at $63,933,000 after purchasing an additional 343,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Haemonetics by 327.0% during the second quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier’s stock worth $25,445,000 after purchasing an additional 235,535 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 0.5 %

Shares of Haemonetics stock opened at $78.13 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics Co. has a 52 week low of $70.25 and a 52 week high of $97.97. The stock has a 50 day moving average price of $82.34 and a two-hundred day moving average price of $80.58. The stock has a market capitalization of $3.92 billion, a PE ratio of 32.42, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. The business had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.99 EPS. As a group, equities analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on HAE. Needham & Company LLC reiterated a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a report on Friday, November 8th. CL King assumed coverage on Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price target for the company. Barrington Research restated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $108.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.